Dr. Daniel Weber

Thoracic medical oncologist · Johns Hopkins · United States (US) · Oncology

Tier 1STK-0062GoodOwner MSL JWJames Whitfield

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: SCLC
Scientific interests: irAE management
Engagement preference: Either
Advisory boards: 2
Publications: 148
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 1: 4 per year (assumption)

Last engaged: 10 May 2026 (128 days ago)
Next planned contact: 09 Aug 2026 Overdue
Last 6 months vs target: 100%
2 of 2 expected engagements

Insights from this stakeholder (2)

INS-0072Chemotherapy-free first line
10 May 2026 · Evidence gap
MediumClosed
INS-0014Duration of response
08 May 2026 · Product understanding
MediumClosed

Engagement history (3)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
10 May 2026	Advisory board	In person	James Whitfield	Vantrexa	Chemotherapy-free first lineInfusion-reaction management	1	—	Reviewed	ENG-0020
08 May 2026	Scientific exchange	In person	James Whitfield	Vantrexa	Duration of responsePD-L1 testing turnaround	1	—	Reviewed	ENG-0041
23 Feb 2026	Scientific exchange	Virtual	James Whitfield	Vantrexa	Elderly / ECOG 2 patients	0	—	Reviewed	ENG-0079

Timeline

10 May 2026
Advisory board
Chemotherapy-free first line, Infusion-reaction management
08 May 2026
Scientific exchange
Duration of response, PD-L1 testing turnaround
23 Feb 2026
Scientific exchange
Elderly / ECOG 2 patients

Related stakeholders (5)

Johns Hopkins

Dr. Javier Ivanova
Radiation oncologist
Tier 1
Dr. Mariana Vogel
Primary care physician
Tier 3
Dr. Javier Ueda
General neurologist
Tier 2
Dr. Andrea Olsen
Allergist
Tier 2
Dr. Rosa Eriksen
Dermatologist
Tier 1